Urothelial cancer      

FOI REFERENCE: 24493 FOI DATE: 5^th November 2024     

How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

Atezolizumab (Tecentriq) 5 Patients

Avelumab (Bavencio) 12 Patients

Carboplatin single agent or in any other combination 10 Patients

Carboplatin with Gemcitabine 7 Patients

Carboplatin with Paclitaxel 0 Patients

Cisplatin single agent or in any other combination 9 Patients

Cisplatin with Gemcitabine 9 Patients

Cisplatin with Gemcitabine + Nivolumab (Opdivo) 0 Patients

Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) 0 Patients

Nivolumab (Opdivo) 0 Patients

Pembrolizumab (Keytruda) 0 Patients

Other active systemic anti-cancer therapy

Palliative care only 27 Patients

Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part? None currently (November 2024)